Lab
Rapid DX Laboratory LLC
Rapid DX Laboratory LLC was paid $928K by Medicaid between Jan 2021 and Oct 2024, across 64 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 26% of everything it billed.
33Billing provider infoRAPID DX LABORATORY LLC
HOUSTON, TX 77040
HOUSTON, TX 77040
33aNPI1174137368assigned 09/03/2020
33bProvider typeClinical Medical Laboratory
28Total paid$928K
24GClaims99,893
24DCodes billed64
24AFirst – last monthJan 2021 – Oct 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Texas
Rank by total paid#72 of 436
Median peer was paid$17K
This provider vs. median54×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 4,639 | $97K | |
| 2022 | 7,700 | $255K | |
| 2023 | 51,088 | $312K | |
| 2024incomplete | 36,466 | $264K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 26% | 5,163 | 3,692 | $242K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 18% | 7,734 | 3,782 | $164K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 10% | 733 | 718 | $96K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 8.6% | 5,144 | 3,684 | $80K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 4.3% | 3,012 | 2,350 | $40K |
| 87631 | 3.8% | 3,271 | 2,492 | $35K | |
| 87481 | 2.7% | 4,966 | 3,330 | $25K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.8% | 791 | 570 | $17K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.6% | 1,993 | 1,309 | $15K |
| 87556 | 1.6% | 4,377 | 3,144 | $15K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.4% | 141 | 113 | $13K |
| 87496 | 1.4% | 4,481 | 3,208 | $13K |
52 more codes
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.4% | 4,368 | $13K |
| 87653 | 1.3% | 4,050 | $12K | |
| 87551 | 1.2% | 2,833 | $11K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.2% | 4,456 | $11K |
| 87561 | 1.0% | 2,825 | $9K | |
| 87641 | <1% | 3,343 | $9K | |
| 87541 | <1% | 3,320 | $9K | |
| 87486 | <1% | 3,319 | $9K | |
| 87500 | <1% | 3,346 | $9K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 775 | $8K |
| 87498 | <1% | 2,766 | $8K | |
| 87581 | <1% | 3,302 | $8K | |
| 87640 | <1% | 4,555 | $8K | |
| 87529 | <1% | 1,666 | $8K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 808 | $7K |
| 87532 | <1% | 2,797 | $6K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 503 | $5K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,594 | $4K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,159 | $3K |
| 87563 | <1% | 1,606 | $3K | |
| 87511 | <1% | 1,041 | $2K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 200 | $1K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 221 | $890.55 |
| 83970 | <1% | 53 | $751.17 | |
| 84403 | <1% | 89 | $740.06 | |
| 84481 | <1% | 133 | $692.63 | |
| 80061 | Lipid panel | <1% | 341 | $638.09 |
| 82607 | <1% | 171 | $603.05 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 298 | $500.83 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 158 | $484.48 |
| 80053 | Comprehensive metabolic panel | <1% | 249 | $460.92 |
| 84439 | <1% | 154 | $410.32 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 318 | $382.75 |
| 82728 | <1% | 115 | $378.90 | |
| 84270 | <1% | 51 | $376.80 | |
| 83002 | <1% | 71 | $370.26 | |
| 83525 | <1% | 73 | $309.19 | |
| 82670 | <1% | 70 | $281.43 | |
| 80050 | General health panel | <1% | 87 | $268.52 |
| 82746 | <1% | 82 | $257.10 | |
| 82533 | <1% | 50 | $254.34 | |
| 83540 | <1% | 144 | $241.97 | |
| 82627 | <1% | 47 | $211.97 | |
| 86376 | <1% | 56 | $183.36 | |
| 84100 | <1% | 107 | $181.00 | |
| 83735 | <1% | 75 | $132.56 | |
| 84153 | <1% | 23 | $127.52 | |
| 81001 | <1% | 122 | $65.31 | |
| 86140 | <1% | 43 | $53.88 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 19 | $28.44 |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | <1% | 20 | $22.92 |
| 80069 | <1% | 15 | $14.58 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDAI, BOSONG (CEO OWNER)
| Provider | Location | Paid |
|---|---|---|
| Genview Diagnosis INC | Houston, TX | $8.93M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.